# DOJ Reschedules Medical Marijuana; States Face New Uncertainty – KOTA > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/doj-medical-marijuana-rescheduling-impact-states-uncertainty/ > **Published:** 2026-06-02T00:52:30-04:00 | **Last Modified / Clinically Audited:** 2026-09-27T21:53:31-04:00 > **Clinical Summary:** Explore the DOJ medical marijuana rescheduling impact on federal policy, research, and state-level uncertainties affecting patients and clinicians. --- ✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchMental HealthPainAnxietyIndustrySafety Why This Matters Clinicians now have stronger legal footing to recommend cannabis for patients, as Schedule III reclassification removes the conflict between federal prohibition and state medical programs. Research barriers are significantly lowered, enabling better evidence generation on efficacy and safety for specific conditions. Patients may face reduced costs through tax deduction eligibility for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) expenses, though state-level implementation inconsistencies will create variable access across jurisdictions. Clinical Summary The Department of Justice’s reclassification of cannabis from Schedule I to Schedule III represents a significant shift in federal drug policy that creates both opportunities and uncertainties for clinicians and patients. This rescheduling facilitates expanded research opportunities and removes certain federal tax barriers that have constrained the cannabis industry, potentially improving product standardization and access to evidence-based information. However, the change creates a complex patchwork where state-level legalization remains inconsistent with federal status, leaving clinicians in legal gray zones regarding prescribing and patient counseling. Healthcare providers must now navigate evolving regulations that vary by state while lacking comprehensive clinical guidelines from major medical organizations, making it difficult to standardize cannabis recommendations in clinical practice. The rescheduling may accelerate pharmacological research that could eventually inform evidence-based dosing and indication protocols, though this research will take years to mature into clinical recommendations. Clinicians should anticipate that patients will increasingly inquire about cannabis for various conditions and should prepare to have informed conversations grounded in current evidence while acknowledging the significant knowledge gaps that remain. Dr. Caplan’s Take “The rescheduling to Schedule III is clinically meaningful because it finally allows us to conduct the rigorous trials we need, but it creates real problems for my patients in states where state law hasn’t caught up with federal policy, leaving them in legal limbo despite having legitimate medical conditions we can treat effectively.” Clinical Perspective The Department of Justice’s rescheduling of cannabis from Schedule I to Schedule III represents a significant shift in the federal regulatory landscape, potentially facilitating research and reducing certain tax barriers for compliant businesses. However, clinicians should recognize that this reclassification does not resolve fundamental uncertainties about cannabis efficacy, optimal dosing, drug interactions, or long-term safety profiles—gaps that persist because Schedule I restrictions have historically limited rigorous [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). The continued tension between state-level legalization and federal scheduling may create confusion about what products are available to patients, how they should be dosed, and what counseling physicians should provide, particularly since state regulations vary widely in product testing standards and labeling requirements. Clinicians should remain cautious about cannabis recommendations pending robust clinical evidence in their specific patient populations, stay informed about their state’s evolving regulations, and consider documenting cannabis use discussions in the medical record to support clinical decision-making and continuity 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20DOJ%20reschedules%20medical%20marijuana%3B%20states%20face%20new%20uncertainty%20-%20KOTA%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57263)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57263)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20DOJ%20reschedules%20medical%20marijuana%3B%20states%20face%20new%20uncertainty%20-%20KOTA%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D57263)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.kotatv.com/2026/06/01/feds-have-embraced-medical-marijuana-now-what/?outputType=amp](https://www.kotatv.com/2026/06/01/feds-have-embraced-medical-marijuana-now-what/?outputType=amp) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Rescheduling marijuana will make it easier to study a drug that tens of millions of Americans …](https://cedclinic.com/rescheduling-marijuana-will-make-it-easier-to-study-a-drug-that-tens-of-millions-of-americans/) Learn how marijuana rescheduling facilitates research on a widely used drug, improving understanding and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). [Read More](https://cedclinic.com/rescheduling-marijuana-will-make-it-easier-to-study-a-drug-that-tens-of-millions-of-americans/) [What new federal marijuana guidelines mean for research and patients. The bottom line](https://cedclinic.com/what-new-federal-marijuana-guidelines-mean-for-research-and-patients-the-bottom-line/) Discover the implications of updated federal marijuana guidelines on [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and patient access. [Explore Insights](https://cedclinic.com/what-new-federal-marijuana-guidelines-mean-for-research-and-patients-the-bottom-line/) [Navigating the Evolving Landscape of Medicinal Cannabis Research: Benefits, Risks, and …](https://cedclinic.com/navigating-the-evolving-landscape-of-medicinal-cannabis-research-benefits-risks-and/) An overview of the benefits and risks in medicinal [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) amid changing legal frameworks. [Learn More](https://cedclinic.com/navigating-the-evolving-landscape-of-medicinal-cannabis-research-benefits-risks-and/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).